A drug that targets a heart receptor to treat right-sided (right ventricular) heart failure
Validation of a novel drug target to treat RV failure
This project will test a drug that activates a specific heart receptor to improve right-sided heart function for people with right ventricular failure, including those with pulmonary hypertension.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Affairs Med Ctr San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11247533 on NIH RePORTER |
What this research studies
From a patient's perspective: researchers are confirming whether turning on the alpha‑1A adrenergic receptor in the right side of the heart can prevent and reverse right ventricular failure. They will use laboratory experiments, animal models, and tissue studies to measure right heart contraction, exercise capacity, muscle protein function, and markers of cell damage after treatment with the drug A61603. The team will also measure oxidative stress and blood markers like troponin and examine cell survival signaling to see if treatment restores healthier heart muscle. If the target is validated, the work would support moving this approach toward human trials.
Who could benefit from this research
Good fit: Ideal candidates for future trials would be people with right ventricular failure, especially those whose RV dysfunction is related to pulmonary hypertension or similar pressure/volume overload conditions.
Not a fit: Patients with heart problems not driven by right ventricular dysfunction or those with severe multi-organ failure or contraindications to adrenergic drugs may not receive benefit.
Why it matters
Potential benefit: If successful, this work could lead to a new medicine that improves right heart function and exercise tolerance for people with right ventricular failure.
How similar studies have performed: Preclinical studies in animal models reported that chronic treatment with the alpha‑1A agonist A61603 both prevented and reversed right ventricular failure, but human testing has not yet been performed.
Where this research is happening
San Francisco, United States
- Veterans Affairs Med Ctr San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Baker, Anthony J. — Veterans Affairs Med Ctr San Francisco
- Study coordinator: Baker, Anthony J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.